Unknown

Dataset Information

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma.


ABSTRACT:

Background

RAS effector signaling pathways such as PI3K/mTOR and ERK are frequently dysregulated in glioblastoma. While small molecule targeted therapies against these pathways have appeared promising in preclinical studies, they have been disappointing in clinical trials due to toxicity and de novo and adaptive resistance. To identify predictors of glioblastoma sensitivity to dual pathway inhibition with mTORC1/2 and MEK inhibitors, we tested these agents, alone and in combination, in a cohort of genomically characterized glioblastoma cell lines.

Methods

Seven genomically characterized, patient-derived glioblastoma neurosphere cell lines were evaluated for their sensitivity to the dual mTORC1/2 kinase inhibitor sapanisertib (MLN0128, TAK-228) alone or in combination with th

SUBMITTER: Schreck KC 

PROVIDER: S-EPMC7668446 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature